Arnold Oronsky
InterWest Partners
Dr. Arnold L. Oronsky has been with InterWest's life sciences team since 1994. He is a board member of the following life science companies: Dynavax Technologies (“DVAX”), Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Integrated Diagnostics, MacroGenics, RadioRx and United States Diagnostic Standards Corp. (USDS).
As a Ph.D. in immunology and senior lecturer at the Department of Medicine at Johns Hopkins Medical School, Dr. Oronsky brings a deep understanding of medical research to finding and investing in successful life sciences companies.
Prior to joining InterWest, Dr. Oronsky was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.
Dr. Oronsky received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.
David Barker
Wellcome Trust
Dr. David L. Barker was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California from 2000 through 2006. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. He currently serves on the Boards of Directors of Cell Biosciences, Integrated Diagnostics, IntegenX Inc., and NextBio, and is a scientific advisor to Illumina, BioNanomatrix, GenVault, Diagnostics for the Real World, Helixis, BiOptix, and DNA Direct.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.
Patrizia Luchetta
Ministry of the Economy and Foreign Trade, Luxembourg
BioTechCube Luxembourg
Patrizia Luchetta heads the Life Sciences and Technologies Department at the Ministry of the Economy and Foreign Trade of the Grand Duchy of Luxembourg. She is also the founding Chair of BioTechCube Luxembourg, a newly formed Luxembourg-based investment firm. She is the lead agent in developing Luxembourg into a health sciences and technologies hub, with the goal of expanding research, business and job opportunities in Luxembourg’s economy. Her expertise over a wide range of disciplines has been instrumental in the success of this program.
Previously, as a parliamentary attaché, she played a key role in the formulation of budgetary, economic and environmental policy. She began her career in the industrial and financial sectors, focusing on marketing and public relations. Her experience also includes working with PAM, a California-based public affairs group specializing in environmental concerns.
Patrizia received both her Bachelor of Science degree in Social Science and Masters of Arts degree in Social Science from the Open University.
Lee Hood
Institute for Systems Biology
An unparalleled pioneer in the translation of technology from R&D to industry, Dr. Hood has co-founded more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. Amgen and Applied Biosystems have a combined market capitalization of over $50B. He is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Indeed, he is one of only 7 members out of more than 6000 that are in all three US National Academies (NAS, IOM, and NAE). Dr. Hood is the recipient of numerous awards including the Lasker Award, Kyoto Prize, Lemelson-MIT Prize for Invention and Innovation among many others. Dr. Hood has over 600 publications, awarded 15 patents and written multiple textbooks in diverse areas.
Jim Heath
California Institute of Technology
Dr. Heath is Gilloon Professor and Professor of Chemistry at the California Institute of Technology. He
received a B.Sc. degree in chemistry from Baylor University in 1984, and a Ph.D. degree in chemistry from
Rice University in 1988, where he studied in the group of Richard E. Smalley. Dr. Heath was a Miller Postdoctoral Fellow at UC Berkeley from 1988 to 1991, and a research staff member at the IBM T.J. Watson Research Labs in Yorktown Heights, New York from 1991 to 1994. In 1994 he left IBM to join the Department
of Chemistry and Biochemistry at UCLA. He was the founding director of the California NanoSystems Institute (CNSI), prior to moving to Caltech in 2003. Heath is a Fellow of the American Physical Society, and his awards include Jules Springer Award in Applied Physics (2000); the Feynman Prize (2000); the Sackler Prize in the Physical Sciences (2001), and the Spiers Medal from the Royal Society (2005). Dr. Heath directs the National Cancer Institute-funded NanoSystems Biology Cancer Center, and has been a founder of a number of startup companies, including MTI (acquired by Siemens in 2005), NanoSys, Inc., and Momentum Biosciences, which is a biotech incubator currently operating in Los Angeles.
Albert A. Luderer, Ph.D.
Chief Executive Officer and Director
Dr. Luderer has more than 30 years of successful leadership in medical diagnostics, laboratory medicine and therapeutic development. Prior to joining Integrated Diagnostics, he served as President, CEO and Director of BioTrove Inc., a venture-backed Molecular Biological Tools company that was acquired by Life Technologies in December 2009. BioTrove was the 2009 recipient of Frost & Sullivan’s North American Drug Discovery Technologies and Growth Strategy Leadership of the Year Award and was recognized by Inc. 5000 as one of the fastest growing companies in North America. Dr. Luderer’s prior positions include: CEO of the venture-backed Therapeutics company Light Sciences Inc.; President and COO of bioMérieux, Inc.; Vice President of Technology and Business Development for Dianon Systems (now Lab Corp); Vice President of Technology Development and Support at Boehringer Mannheim (Now Roche) and; Head of Biomedical Research for Corning. Dr. Luderer has developed and commercialized major In Vitro Diagnostic (IVD) systems including the global market leader for microbial detection and antibiotic susceptibility testing - Vitek®II, co-invented and established Standard of Care Diagnostics in cancer detection and has participated in the creation of one of the dominant global IVD companies - Siemens Diagnostics - through his participation in the negotiation and formation of the joint venture IVD firm Ciba Corning. Dr. Luderer holds a PhD from Rutgers University where he was an NSF pre doctoral fellow and performed post graduate work in immunology at Jefferson Medical College. He is an independent director of Agendia BV and Micronics Inc. He is an advisor to Washington University’s Biomedical Engineering program.